Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Michael C. Mithoefer, Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin
Psychopharmacology (Berl) November 1, 2024 DOI: 10.1007/s00213-024-06666-x via PubMed Central
Summary
AI-generated from the abstractThis is a retraction note for a previously published article about MDMA-assisted psychotherapy for PTSD. The original article described the design and rationale for phase 3 trials, which were based on a pooled analysis of six phase 2 randomized controlled trials. The retraction indicates that the original article should not be relied upon, but the note itself does not provide any findings or data about the treatment's effectiveness.
Study at a glance
| Characteristics | Randomized Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Significantly reduce symptoms Innovative treatment strategy Effective PTSD Treatment MDMA-Assisted Psychotherapy MDMA Specialized psychotherapy |
| Citations | 9 |
Abstract
Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.